S-1: FOXO Technologies Files for Resale of Up to 4 Million Shares Amid Financial Uncertainty

FOXO Technologies is registering the resale of up to 4 million shares of Class A Common Stock by selling stockholders, as the company grapples with funding its operations beyond December 2025.

Summary

• FOXO Technologies Inc. has filed a registration statement for the offer and resale of up to 4,000,000 shares of Class A Common Stock.
• These shares are issuable upon the conversion of Series A Cumulative Convertible Redeemable Preferred Stock held by certain selling stockholders.
• The company will not receive any proceeds from the sale of these shares by the selling stockholders.
• The selling stockholders may sell the shares from time to time through public or private transactions at prevailing market prices or negotiated prices.
• FOXO Technologies is currently listed on the NYSE American under the symbol FOXO, with its public warrants quoted on the OTC Pink Marketplace under the symbol FOXOW.
• The company's independent registered public accounting firm has raised concerns about its ability to continue as a going concern.
• FOXO expects to be able to fund operations through December 2025, but will need additional financing beyond that date.
• The company has recently acquired Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc. to expand its operations into the healthcare sector.
• Through the voting rights of its Series A Preferred Stock, RHI controls a majority of the voting power of FOXO Technologies.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the company's financial instability, reliance on future capital raises, and the potential for stock dilution from the resale of shares. While there are some positive aspects, such as the acquisitions and patent allowances, the overall outlook is concerning.

Positives

• FOXO Technologies has taken actions to bolster its cash position, including raising funds through private offerings and reducing employee headcount.
• The company has acquired Myrtle Recovery Centers, Inc. and Rennova Community Health, Inc., expanding its operations into the healthcare sector.
• FOXO believes there is growing demand for direct-to-consumer wellness testing and epigenetic data analysis tools.
• The USPTO has issued Notices of Allowance to FOXO for two patents for the use of machine learning techniques to enable the commercialization of epigenetic biomarkers.

Negatives

• FOXO Technologies does not have sufficient capital to fund its operations beyond December 2025.
• The company's independent registered public accounting firm has raised concerns about its ability to continue as a going concern.
• Sales of a substantial number of shares by the selling stockholders could depress the market price of the Common Stock and Public Warrants.
• RHI controls a majority of the voting power of FOXO Technologies, limiting the voting power of other stockholders.

Risks

• Sales of a substantial number of shares by the selling stockholders could depress the market price of the Common Stock and Public Warrants.
• The company's ability to continue as a going concern is uncertain.
• The company will need additional financing to fund its operations beyond December 2025.
• RHI's control of a majority of the voting power could limit minority shareholders' ability to influence corporate affairs.
• The company operates in a very competitive and rapidly changing environment.

Future Outlook

Based on its current operating plan, FOXO expects to be able to fund its operations through December 2025, but will need additional financing or other increase in its cash and cash equivalents balance to enable it to fund its operations beyond December 31, 2025.

Industry Context

FOXO Technologies is operating in the healthcare services and technology industry, with a focus on epigenetics, behavioral health, and rural healthcare. The company's acquisitions of Myrtle Recovery Centers and Rennova Community Health reflect a trend of consolidation and diversification in the healthcare sector. The company's focus on direct-to-consumer wellness testing and epigenetic data analysis aligns with the growing interest in personalized medicine and preventative healthcare.

Comparison to Industry Standards

• It's difficult to directly compare FOXO's financial performance to industry standards due to its unique combination of healthcare services and technology.
• However, the company's net losses and concerns about its ability to continue as a going concern raise red flags compared to more established players in the healthcare and technology sectors.
• Comparable companies in the rural hospital space include Community Health Systems and LifePoint Health, while companies in the behavioral health space include Acadia Healthcare and Universal Health Services.
• In the epigenetics space, companies like Illumina and Exact Sciences are key players, but FOXO's focus on saliva-based testing and AI-driven analysis differentiates it from these companies.

Stakeholder Impact

• Shareholders may experience a decline in the value of their shares due to the potential for stock dilution and the company's financial instability.
• Employees may be affected by potential cost-cutting measures or restructuring efforts.
• Customers may be impacted by changes in the company's product and service offerings.
• Suppliers and creditors may face increased risk due to the company's financial challenges.

Next Steps

• The selling stockholders may offer and sell the securities covered by this prospectus in a number of different ways, at varying prices and for varying gains.
• The company will need to secure additional financing to fund its operations beyond December 2025.
• The company intends to leverage the extensive epigenetic data it has generated in its clinical trials and the expertise of its team and continue building strategic alliances with new partners in academia, business, healthcare and government.
• The company also intends to frequently evaluate and develop commercialization opportunities for its product and service offerings and its research findings.

Key Dates

Keywords

FOXO Technologies, Class A Common Stock, Series A Preferred Stock, Resale, Selling Stockholders, Financial Uncertainty, Going Concern, Myrtle Recovery Centers, Rennova Community Health, Epigenetics, Healthcare, Sabby Volatility, Sabby Healthcare, RHI, Reverse Stock Split